---
title: "Immuron surges 71% during regular trading on exclusive US distribution deal"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298047958.md"
description: "Immuron shares jumped 71% as the company announced an exclusive agreement with Calmino to distribute PROIBS in the US gut health market."
datetime: "2026-09-04T13:49:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298047958.md)
  - [en](https://longbridge.com/en/news/298047958.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298047958.md)
generator: "portal-rs"
---

# Immuron surges 71% during regular trading on exclusive US distribution deal

Immuron(IMRN.US) 盘中涨超 71%，现报**1.90**美元。

消息面上，Immuron 宣布与 Calmino group AB 达成独家分销协议，将在美国推出肠道健康产品 PROIBS。该产品为欧洲认证的医疗器械，用于缓解腹部疼痛和肠道问题，目标市场为规模达**41.6 亿**美元的美国肠道健康领域。

PROIBS 在欧洲市场已有超过十年销售历史，在可用性研究中获得了积极的用户反馈。此次合作将帮助 Immuron 将其消化健康产品组合扩展至美国市场，超出其在澳大利亚的原有业务范围。

### Related Stocks

- [IMRN.US](https://longbridge.com/en/quote/IMRN.US.md)

## Related News & Research

- [Immuron To Launch PROIBS In U.S. After Australia Debut; Pre-market Shares Up](https://longbridge.com/en/news/298028882.md)
- [Immuron to launch PROIBS® in the United States | IMRN Stock News](https://longbridge.com/en/news/298022732.md)
- [Immuron FY26 net sales rise 6% to AUD 7.7 million](https://longbridge.com/en/news/297303231.md)
- [Immuron posts CEO presentation for TechKnow Invest Roadshow](https://longbridge.com/en/news/293928783.md)
- [Immuron Seeks Transformational Partnership for C. difficile Drug IMM-529](https://longbridge.com/en/news/291732514.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**